HLS Therapeutics (TSE:HLS) Upgraded at Canaccord Genuity Group

Canaccord Genuity Group upgraded shares of HLS Therapeutics (TSE:HLS) from a hold rating to a buy rating in a research report report published on Thursday morning, Marketbeat reports.

HLS Therapeutics Price Performance

HLS Therapeutics stock opened at C$3.90 on Thursday. The company has a debt-to-equity ratio of 75.86, a quick ratio of 1.01 and a current ratio of 1.05. HLS Therapeutics has a 52 week low of C$3.77 and a 52 week high of C$5.77. The stock has a market capitalization of C$121.97 million, a P/E ratio of -12.19 and a beta of -0.18. The stock has a fifty day moving average of C$4.22 and a 200-day moving average of C$4.41.

HLS Therapeutics (TSE:HLS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported C($0.03) earnings per share for the quarter. The business had revenue of C$14.67 million for the quarter. HLS Therapeutics had a negative return on equity of 14.39% and a negative net margin of 15.26%.During the same period in the prior year, the company posted ($0.09) EPS. On average, sell-side analysts expect that HLS Therapeutics will post -0.12 earnings per share for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.